Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606164 | 0.92 | NMT1 (0.56) | SLC6A5CPB2SLC15A2ERAP2ERAP1 | |
| SCHEMBL11974536 | 0.91 | ALDH1A1 (0.50) | SLC6A5CPB2ERAP2ERAP1LNPEP | |
| SCHEMBL29904373 | 0.90 | SLC15A2 (0.55) | SLC6A5CPB2SLC15A2ERAP2ERAP1 | |
| SCHEMBL30394925 | 0.90 | SLC15A2 (0.55) | SLC6A5CPB2SLC15A2ERAP2ERAP1 | |
| SCHEMBL30918795 | 0.89 | SLC15A2 (0.43) | SLC6A5CPB2SLC15A2ERAP2ERAP1 | |
| SCHEMBL30718965 | 0.88 | ERAP2 (0.44) | SLC6A5CPB2SLC15A2ERAP2ERAP1 | |
| SCHEMBL11127918 | 0.88 | ALDH1A1 (0.49) | FOLH1OPRK1 | |
| SCHEMBL30537470 | 0.87 | NMT2 (0.47) | SLC6A5CPB2ERAP2ERAP1LNPEP | |
| SCHEMBL29987029 | 0.86 | ERAP2 (0.55) | SLC6A5CPB2ERAP2ERAP1LNPEP | |
| SCHEMBL29531597 | 0.86 | NMT1 (0.49) | SLC6A5CPB2SLC15A2NMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617856-B2 | Protease-cleavable substrates and methods of use thereof | CYTOMX THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250215095-A1 | PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617856-B2 | Protease-cleavable substrates and methods of use thereof | CTSL, SPPL2B, SPPL2A | SLC6A5 3206/4885CPB2 79/4885SLC15A2 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.